Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Fallopian Tube Cancer; Ovarian Sarcoma; Ovarian Stromal Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Uterine Sarcoma; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IV Endometrial Carcinoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Uterine Sarcoma; Stage IV Vulvar Cancer; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer
Interventions: Radiation: stereotactic radiosurgery; Procedure: quality-of-life assessment
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine and Pazopanib
Sponsor: Washington University School of Medicine
Not yet recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Polycystic Ovary Syndrome
Intervention: Behavioral: Nutrition Education, Dietary Counseling, and Cooking
Sponsors: Children's Hospital Boston; Thrasher Research Fund
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; Colon Cancer; Ovarian Cancer; Endometrium Cancer
Intervention: Drug: BKM120
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Epithelial Ovarian Cancer
Intervention: Biological: MUC1 Dendritic Cell Vaccine (CVac)
Sponsors: Prima BioMed Ltd; SPRI Clinical Trials Global, LLC; Clininvent Research Pvt. Ltd; Sciformix Technologies Private Limited; CPR Pharma Services Pty Ltd; Progenitor Cell Therapy LLC; Cell Therapies Pty Ltd
Not yet recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Polycystic Ovarian Syndrome
Interventions: Drug: Endometrin (progesterone 100mg vaginal inserts); Drug: Metformin
Sponsors: Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery; Other: pharmacological study; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Genetic: protein expression analysis
Sponsor: University of Nebraska
Recruiting - verified February 2010
Conditions: Pancreatic Cancer; Liver Cancer; Lung Cancer
Intervention: Procedure: MR Imaging
Sponsors: Stanford University; American Association of Physicists in Medicine
Recruiting - verified February 2010
Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Advanced Pancreatic Cancer
Intervention: Drug: Tarceva, Gemcitabine, Nab-Paclitaxel
Sponsors: OSI Pharmaceuticals; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: belinostat; Drug: carboplatin
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: ABT-888; Drug: carboplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Sorafenib and Everolimus
Sponsors: Roswell Park Cancer Institute; Novartis; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2010
Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Interventions: Dietary Supplement: Cinnamon Supplementation; Dietary Supplement: Placebo (wheat flour)
Sponsor: Pennington Biomedical Research Center
Recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer; Solid Tumors
Intervention: Drug: GSK1120212 plus everolimus
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ovarian Cancer
Intervention: Procedure: DCE-MRI scans
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Biological: Placebo of Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Drug: cyclophosphamide; Drug: sodium chloride
Sponsor: EMD Serono
Recruiting - verified March 2010
Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified December 2009
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3; Drug: liposomal doxorubicin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: proteomic profiling; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2008
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Ovarian Cancer; Endometrial Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
Intervention: Behavioral: online platform "STAR" (Symptom Tracking and Reporting for Patients)
Sponsors: Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: Ipilimumab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified February 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2009
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: dasatinib; Drug: etoposide phosphate; Drug: ifosfamide; Genetic: microarray analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sarcoma
Interventions: Other: educational intervention; Other: informational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Tufts Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: Part 2, Cohort A: AMG 386 MTD Part 1 + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B2: AMG 386 3mg/kg + Topotecan; Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A2: AMG 386 3mg/kg + Liposomal doxorubicin; Drug: Part 2, Cohort B: AMG 386 MTD part 1 + Topotecan
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Solid Tumors; Ovarian Neoplasms; Prostate Cancer
Interventions: Drug: Comparator: MK4827 (PARP inhibitor); Drug: Comparator: MK4827 (PARP Inhibitor)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: pegylated liposomal doxorubicin (PLD); Drug: EC20; Drug: EC20
Sponsor: Endocyte
Recruiting - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ovarian Cancer
Intervention:
Sponsor: University of Alabama at Birmingham
Recruiting - verified February 2010
Condition: Pancreatic Neoplasm
Interventions: Biological: monoclonal antibody; Drug: chemotherapy
Sponsors: Pfizer; University of Pennsylvania
Recruiting - verified March 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Adrenocortical Carcinoma; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab; Drug: temsirolimus
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Breast Cancer; Cancer of the Breast; Neoplasms, Breast
Intervention: Drug: Estrace followed by anastrazole
Sponsors: Fox Chase Cancer Center; Kimmel Cancer Center (KCC)
Recruiting - verified February 2010
Condition: Adenocarcinoma of the Ovary
Intervention: Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Sponsor: AVAX Technologies
Recruiting - verified March 2010
Conditions: Cholangiocarcinoma Cancer; Gallbladder Cancer; Pancreatic Cancer; Ampullary Cancer
Interventions: Drug: Gemcitabine and Docetaxel (Chemotherapy); Radiation: XRT at 5040 or 5400 cGy and 5FU (Radiation and Chemotherapy); Drug: Gemcitabine and Docetaxel (Chemotherapy)
Sponsor: Washington University School of Medicine
Recruiting - verified February 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Head and Neck Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: capecitabine; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Biological: IMMU-107 (hPAM4)
Sponsor: Immunomedics, Inc.
Recruiting - verified February 2010
Conditions: Esophageal Cancer; Bile Duct Neoplasms; Gastric Cancer; Liver Cancer; Melanoma; Pancreatic Cancer; Sarcoma
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Drug: Capecitabine, Tarceva
Sponsors: Penn State University; Genentech
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Behavioral: Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Conditions: Ovarian Cancer; Peritoneum Tumors
Intervention: Behavioral: Data Collection
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: dasatinib; Other: laboratory biomarker analysis; Other: physiologic testing
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: levonorgestrel; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: aflibercept; Drug: docetaxel
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2007
Conditions: Neuroendocrine Tumor; Islet Cell Tumor
Interventions: Drug: Sunitinib malate; Procedure: Hepatic Artery Embolizations
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Pfizer
Recruiting - verified February 2010
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Drug: LY573636
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate; Drug: octreotide acetate; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Procedure: computed tomography
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine/Fluorouracil with External Beam Radiation
Sponsor: University of Massachusetts
Recruiting - verified March 2010
Conditions: Gastric Cancer; Pancreatic Cancer; Cervical Cancer; Vulvar Cancer; Endometrial Cancer; Anal Cancer
Interventions: Behavioral: Interview; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endocrine Tumors
Interventions: Drug: lanreotide (Autogel formulation); Other: Placebo
Sponsor: Ipsen
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: moxifloxacin hydrochloride
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Osteoporosis; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: cholecalciferol; Drug: calcium gluconate; Drug: zoledronic acid
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2); Osteoporosis; Ovarian Cancer
Interventions: Drug: zoledronic acid; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Intervention: Drug: sorafenib tosylate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: sorafenib tosylate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Pancreatic Neoplasms; Adenocarcinoma
Intervention: Drug: Curcumin
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Oral Complications; Ovarian Cancer; Pain; Sarcoma
Interventions: Procedure: management of therapy complications; Procedure: pain therapy
Sponsor: Medical College of Wisconsin
Recruiting - verified June 2009
Conditions: Birt Hogg Dube Syndrome; Hereditary Papillary Renal Cell Carcinoma; Kidney Cancer; Multiple Endocrine Neoplasia; Von Hippel-Lindau Syndrome
Interventions: Genetic: DNA ploidy analysis; Genetic: genetic linkage analysis; Genetic: mutation analysis; Genetic: polymorphic microsatellite marker analysis; Other: medical chart review
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Adrenal Gland Neoplasm
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2010
All Categories ... by Medical Condition » ... Cancers » ... Endocrine 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
